Pavel Vodárek

4PUBLICATIONS
18CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cellular immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 12, 2026
Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

|Aug 09, 2024
Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy.

Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová

|Nov 28, 2022
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia.

Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová

|Oct 06, 2020
Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia.

Martin Šimkovič, Pavel Vodárek, Monika Motyčková

Pageof 1

Frequent Collaborators

4 joint publications

Martin Šimkovič

4 joint publications

Lukáš Smolej

3 joint publications

Dominika Écsiová

3 joint publications

Pavel Žák